Dsrna targeting lpa and use thereof

A dsRNA targeting LPA is developed to address the inadequacies of current therapies by specifically interfering with LPA expression, enhancing treatment efficacy for related diseases.

HK40135736APending Publication Date: 2026-07-31TUOJIE BIOTECH (SHANGHAI) CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK62026124170
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-10-25
Filing Date
2026-06-01
Publication Date
2026-07-31

AI Technical Summary

Technical Problem

Current therapies for diseases related to lysophosphatidic acid (LPA) are inadequate in effectively targeting and modulating its expression, leading to insufficient treatment efficacy.

Method used

Development of a double-stranded ribonucleic acid (dsRNA) that specifically targets LPA, interfering with its expression to prevent and treat related diseases.

Benefits of technology

The dsRNA effectively modulates LPA expression, providing a more targeted and effective therapeutic approach for related diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000060_0000
    Figure 00000060_0000
  • Figure 00000060_0001
    Figure 00000060_0001
  • Figure 00000061_0000
    Figure 00000061_0000
Patent Text Reader

Abstract

The invention relates to dsRNA (double-stranded ribonucleic acid) targeting LPA (lipopolysaccharide) and application The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting LPA and a preparation method thereof. The invention also relates to a pharmaceutical composition, a cell or a kit comprising the dsRNA. The dsRNA can interfere with the expression of LPA and prevent and / or treat related diseases.
Need to check novelty before this filing date? Find Prior Art

Description

(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202480028437.8 (22) Application Date 2024.05.31 (66) Domestic Priority Data 202310628559.8 2023.05.31 CN 202311386740.9 2023.10.25 CN (85) PCT International Application Entering National Phase Date 2025.10.27 (86) PCT International Application Application Data PCT / CN2024 / 096731 2024.05.31 (87) PCT International Application Publication Data WO2024 / 245410 ZH 2024.12.05 (71) Applicant Shanghai Tuojie Biomedical Technology Co., Ltd. Address 201203 Room 103, Building 14, No. 3728 Jinke Road, Shanghai Pudong New Area Free Trade Zone (72) Inventors: Li Yunfei, Zhang Zhen, Lin Xiaoyan, Wang Yanhui (74) Patent Agency: Beijing Gecheng Intellectual Property Agency Co., Ltd. 11314 Patent Attorney: Cheng Wei (51) Int.Cl. A61K 47 / 54 (2006.01) C12N 15 / 113 (2006.01) A61K 31 / 713 (2006.01) C12N 15 / 11 (2006.01) C07K 14 / 47 (2006.01) (54) Invention Title: A dsRNA Targeting LPA and Its Application (57) Abstract: A dsRNA targeting LPA and its application. A double-stranded ribonucleic acid (dsRNA) targeting LPA and its preparation method. A pharmaceutical composition, cell or kit containing the dsRNA. dsRNA can interfere with LPA expression, preventing and / or treating related diseases. CN 121079106 A 2025.12.05 CN 1 21 07 91 06 A